Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use levetiracetam tablets safely and effectively. See full prescribing information for levetiracetam tablets.Levetiracetam Tablets USP, for oral use Initial U.S. Approval: 1999
Medication labelWhy this: Advisory · dailymed-prescription
Levetiracetam tablets USP are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. Information describing the use of levetiracetam in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.'s levetiracetam tablets. However, due to UCB, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Levetiracetam tablets USP are indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. Levetiracetam tablets USP are indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.
- generic_name
- levetiracetam
- product_names
- Levetiracetam
- ndc
- 33261-644, 68180-112, 33261-644-30, 33261-644-60, 33261-645, 68180-113, 33261-645-30, 33261-645-60, 33261-646, 68180-114, 33261-646-60, 33261-646-90
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en